Clinical Trials · NCT05649137

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

CompletedPhase 3Semaglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
512
Start date
Jan 2023
Locations
76 sites, 8 countries
Primary endpoint
Relative Change in Body Weight
View Semaglutide compound reference